A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants

Locations

Germany

Start date

17/06/2026

Identifiers

Trial ID NN6706-8230,
NCT number NCT07656454,
Eudract number Not Available

Summary

This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people. This will help us find the best way to give the medicine to people living with heart failure. The study will assess what the body does to the medicine, and how safe it is.

Trial Overview:

Condition

Healthy Volunteers

Heart Failure

Treatment

DRUG: CDR132L (i.v.)

DRUG: CDR132L (s.c.)

Study type

INTERVENTIONAL

Trial duration

Jun 17 2026 - Dec 31 2026

Participants

Phase

Are you eligible?

Gender

Male and female

Age

18 to 55 years old

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.